학술논문
PET Imaging in Preclinical Anti-A[beta] Drug Development
Expert Review
Expert Review
Document Type
Academic Journal
Author
Source
Pharmaceutical Research. July 2022, Vol. 39 Issue 7, p1481, 16 p.
Subject
Language
English
ISSN
0724-8741
Abstract
Author(s): Stina Syvänen [sup.1], Silvio R. Meier [sup.1], Sahar Roshanbin [sup.1], Mengfei Xiong [sup.1], Rebecca Faresjö [sup.1], Tobias Gustavsson [sup.1], Gillian Bonvicini [sup.1] [sup.2], Eva Schlein [sup.1], Ximena Aguilar [sup.1], [...]
Positron emission tomography (PET), a medical imaging technique allowing for studies of the living human brain, has gained an important role in clinical trials of novel drugs against Alzheimer's disease (AD). For example, PET data contributed to the conditional approval in 2021 of aducanumab, an antibody directed towards amyloid-beta (A[beta]) aggregates, by showing a dose-dependent reduction in brain amyloid after treatment. In parallel to clinical studies, preclinical studies in animal models of A[beta] pathology may also benefit from PET as a tool to detect target engagement and treatment effects of anti-A[beta] drug candidates. PET is associated with a high level of translatability between species as similar, non-invasive protocols allow for longitudinal rather than cross-sectional studies and can be used both in a preclinical and clinical setting. This review focuses on the use of preclinical PET imaging in genetically modified animals that express human A[beta], and its present and potential future role in the development of drugs aimed at reducing brain A[beta] levels as a therapeutic strategy to halt disease progression in AD.
Positron emission tomography (PET), a medical imaging technique allowing for studies of the living human brain, has gained an important role in clinical trials of novel drugs against Alzheimer's disease (AD). For example, PET data contributed to the conditional approval in 2021 of aducanumab, an antibody directed towards amyloid-beta (A[beta]) aggregates, by showing a dose-dependent reduction in brain amyloid after treatment. In parallel to clinical studies, preclinical studies in animal models of A[beta] pathology may also benefit from PET as a tool to detect target engagement and treatment effects of anti-A[beta] drug candidates. PET is associated with a high level of translatability between species as similar, non-invasive protocols allow for longitudinal rather than cross-sectional studies and can be used both in a preclinical and clinical setting. This review focuses on the use of preclinical PET imaging in genetically modified animals that express human A[beta], and its present and potential future role in the development of drugs aimed at reducing brain A[beta] levels as a therapeutic strategy to halt disease progression in AD.